150 related articles for article (PubMed ID: 23562130)
1. Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer.
Kalder M; Hans D; Kyvernitakis I; Lamy O; Bauer M; Hadji P
J Clin Densitom; 2014; 17(1):66-71. PubMed ID: 23562130
[TBL] [Abstract][Full Text] [Related]
2. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
[TBL] [Abstract][Full Text] [Related]
3. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Aihara T; Suemasu K; Takei H; Hozumi Y; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
Oncology; 2010; 79(5-6):376-81. PubMed ID: 21430407
[TBL] [Abstract][Full Text] [Related]
4. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
[TBL] [Abstract][Full Text] [Related]
5. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
6. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
Hadji P; Ziller M; Kieback DG; Dornoff W; Tessen HW; Menschik T; Kuck J; Melchert F; Hasenburg A
Ann Oncol; 2009 Jul; 20(7):1203-9. PubMed ID: 19218306
[TBL] [Abstract][Full Text] [Related]
7. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.
Hadji P; Asmar L; van Nes JG; Menschik T; Hasenburg A; Kuck J; Nortier JW; van de Velde CJ; Jones SE; Ziller M
J Cancer Res Clin Oncol; 2011 Jun; 137(6):1015-25. PubMed ID: 21170551
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
9. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
Jones S; Stokoe C; Sborov M; Braun M; Ethirajan S; Kutteh L; Pippen J; Patel M; Paul D; Blum JL; Holmes FA; Myron MC; Cantrell J; Hartung NL; Look RM; Di Salle E; Davis JC; Ilegbodu D; Asmar L
Clin Breast Cancer; 2008 Dec; 8(6):527-32. PubMed ID: 19073509
[TBL] [Abstract][Full Text] [Related]
10. Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene.
Tiitinen A; Nikander E; Hietanen P; Metsä-Heikkilä M; Ylikorkala O
Maturitas; 2004 Jul; 48(3):321-7. PubMed ID: 15207898
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5-year adjuvant treatment in postmenopausal women with early-stage breast cancer.
Hirano A; Inoue H; Ogura K; Hattori A; Yukawa H; Sakaguchi S; Matsuoka A; Tanaka N; Kodera A; Kamimura M; Naritaka Y; Shimizu T
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e238-e242. PubMed ID: 29932305
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
Gonnelli S; Cadirni A; Caffarelli C; Petrioli R; Montagnani A; Franci MB; Lucani B; Francini G; Nuti R
Bone; 2007 Jan; 40(1):205-10. PubMed ID: 16904960
[TBL] [Abstract][Full Text] [Related]
13. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Fan M; Kim D
Breast Cancer Res Treat; 2009 Nov; 118(1):81-7. PubMed ID: 19308727
[TBL] [Abstract][Full Text] [Related]
14. Effects of anti-resorptive agents on trabecular bone score (TBS) in older women.
Krieg MA; Aubry-Rozier B; Hans D; Leslie WD;
Osteoporos Int; 2013 Mar; 24(3):1073-8. PubMed ID: 23052939
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
16. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.
Powles TJ; Hickish T; Kanis JA; Tidy A; Ashley S
J Clin Oncol; 1996 Jan; 14(1):78-84. PubMed ID: 8558225
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women.
Ward RL; Morgan G; Dalley D; Kelly PJ
Bone Miner; 1993 Aug; 22(2):87-94. PubMed ID: 8251768
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women.
Cigler T; Richardson H; Yaffe MJ; Fabian CJ; Johnston D; Ingle JN; Nassif E; Brunner RL; Wood ME; Pater JL; Hu H; Qi S; Tu D; Goss PE
Breast Cancer Res Treat; 2011 Apr; 126(2):453-61. PubMed ID: 21221773
[TBL] [Abstract][Full Text] [Related]
19. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years.
Love RR; Barden HS; Mazess RB; Epstein S; Chappell RJ
Arch Intern Med; 1994 Nov; 154(22):2585-8. PubMed ID: 7979855
[TBL] [Abstract][Full Text] [Related]
20. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.
Goss PE; Qi S; Josse RG; Pritzker KP; Mendes M; Hu H; Waldman SD; Grynpas MD
Bone; 2004 Mar; 34(3):384-92. PubMed ID: 15003786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
